Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
701-720 of 991 trials

Inclisiran for Children with High Cholesterol

We are studying the safety and effectiveness of inclisiran in children aged 2 to under 12 years with homozygous familial hypercholesterolemia. The goal is to see if it can lower their cholesterol levels compared to a placebo.

Homozygous Familial Hypercholesterolemia>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPediatrics

Progressive Multiple Sclerosis: IMU-838 Study

We are testing a new medication, IMU-838, to see if it helps reduce brain atrophy in patients with progressive multiple sclerosis. This study compares its effects to a placebo to evaluate its safety and tolerability.

Progressive Multiple Sclerosis>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Seminomas: EDEN Study on Reduced Therapy

We are testing a less intense treatment for patients with stage IIa/IIb seminomas under 3 cm to see if it helps prevent relapse. We’re also evaluating a biomarker to understand treatment response and its effects on quality of life.

Stage IIa/IIb Seminoma>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementOncology

Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease: CTX001 Treatment

We are studying a new gene therapy using modified stem cells for adolescents and adults with transfusion-dependent β-thalassemia or severe sickle cell disease. The goal is to evaluate its effectiveness and safety in improving their condition.

Transfusion-dependent β-thalassemiaSevere sickle cell disease1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematology

Reducing Anxiety in Children: Multimedia vs. Midazolam

We are studying whether using an iPad can help reduce anxiety in young children before surgery, compared to traditional medication. This trial focuses on children aged 1 to 8 years undergoing day-care procedures.

Perioperative Anxiety in Children6-12 monthsMonitoring phase (IV)Standard MedicinesCost ReimbursementInternal MedicineOtolaryngologyPediatricsPsychiatry

Plaque Psoriasis: Bimekizumab vs. Topical Corticosteroids

We are studying whether bimekizumab can better control plaque psoriasis compared to standard topical treatments. This trial aims to improve disease management and quality of life for patients.

Eruptive Psoriasis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementDermatology

Dazukibart for Idiopathic Inflammatory Myopathies

We are studying the long-term safety and effectiveness of dazukibart in people with dermatomyositis or polymyositis who have completed prior treatment. This research aims to understand how well the medication works in reducing symptoms and improving health.

Idiopathic Inflammatory Myopathy1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesRheumatology

Alzheimer's Dementia: ITI-1284 for Agitation

We are studying whether ITI-1284 can help reduce agitation in patients with Alzheimer's dementia compared to a placebo. The trial will also assess the safety and tolerability of this new treatment.

Alzheimer's Disease3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Painful Diabetic Peripheral Neuropathy: VX-993 Study

We are evaluating a new oral medication, VX-993, for people with pain from diabetic peripheral neuropathy. The study aims to determine if it effectively reduces pain and is safe to use.

Diabetic Peripheral Neuropathic Pain3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementDiabetologyNeurology

Ulcerative Colitis in Kids: Risankizumab Study

We are evaluating how well Risankizumab works and its safety for children aged 2 to under 18 with moderately to severely active ulcerative colitis. This study will help us understand how the drug is processed in their bodies.

Ulcerative Colitis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyPediatrics

Psoriasis: [18F]Fluoride PET-CT Imaging Study

We are investigating if [18F]Fluoride PET-CT scans can detect early bone changes in psoriasis patients at risk for psoriatic arthritis. This study aims to see if this imaging method is effective for early detection.

Psoriasis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyRheumatology

Lichen Simplex Chronicus: Dupilumab Injections

We are studying whether dupilumab injections can help reduce itching in adults with Lichen Simplex Chronicus who haven't found relief from other treatments. The trial will also look at how this treatment affects sleep and overall quality of life.

Neurodermatitis6-12 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementAllergologyDermatology

Chronic Spontaneous Urticaria: BP11 vs. Xolair

We are comparing a new treatment, BP11, to Xolair for patients with chronic spontaneous urticaria who haven't responded to antihistamines. The goal is to see if BP11 is as effective and safe as Xolair.

Chronic Spontaneous Urticaria6-12 monthsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Chronic Low Back Pain: Melatonin Study

We are investigating whether melatonin can help reduce pain in patients with chronic low back pain. Participants will compare its effects to a placebo over six weeks.

Chronic Low Back Pain6-12 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

Avacopan for Children with Active ANCA-associated Vasculitis

We are studying how well Avacopan works when combined with other treatments in children aged 6 to under 18 with active ANCA-associated vasculitis. The trial will also look at safety and how children respond to the medication.

ANCA-associated Vasculitis1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Gastroenteropancreatic Neuroendocrine Tumors: New Liver Treatment

We are studying a new way to deliver radiolabeled treatments directly to the liver for patients with GEP-NET and dominant liver metastases. This trial aims to see if this method improves treatment effectiveness and safety.

Gastroenteropancreatic Neuroendocrine Tumors>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal MedicineOncology

Thyroid Eye Disease: TOUR006 Treatment Study

We are investigating whether the new treatment TOUR006 can reduce eye bulging in adults with thyroid eye disease. Participants will receive either the treatment or a placebo to compare effects.

Thyroid Eye Disease1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementEndocrinologyOphthalmology

Advanced Solid Tumors: OSE-279 Treatment Study

We are investigating a new monoclonal antibody, OSE-279, for patients with advanced solid tumors or lymphomas. The study aims to find the best dose and evaluate its safety and effectiveness compared to existing treatments.

Stage IV Non-Small Cell Lung CancerAdvanced Solid TumorsLymphoma1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Gastrointestinal Stromal Tumors: IDRX-42 Treatment Study

We are testing a new treatment called IDRX-42 for individuals with advanced gastrointestinal stromal tumors that cannot be surgically removed. The study aims to find a safe dosage and assess how well it works against the cancer.

Gastrointestinal Stromal Tumor (GIST)1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyOncology

Sepsis-Induced Hypotension: REGN7544 Treatment Study

We are studying REGN7544 to see if it can help adults with sepsis-induced hypotension manage their blood pressure and reduce the need for other medications. The trial will also assess the safety and effects of this treatment.

Sepsis-Induced Hypotension3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInfectious Diseases